Clinical Research Directory

Inclusion Criteria: * Age at least 18 years; * Elective indication for left pancreatectomy for proven or suspected PDAC; * Upfront resectable or borderline-resectable PDAC in the pancreatic neck, body or tail, according to the National Comprehensive Cancer Network® (NCCN®); o Patients receiving neo-adjuvant treatment can be included in the trial, if the tumor was upfront resectable or borderline-resectable before the start of neoadjuvant therapy. Patients receiving induction therapy for locally advanced pancreatic cancer (LAPC) will be excluded. * Spleen preservation using SPLP with the Warshaw (splenic vessel-resecting) procedure including Gerota's fascia (i.e. circumferentially radical) is feasible according to the local treatment team; * Fit to undergo left pancreatectomy according to the surgeon and anesthesiologist; * Written informed consent. Exclusion Criteria: * Preoperative imaging indicating (possible) tumor involvement of the perisplenic LNs (LN station 10 and perisplenic fat); * Distance between the left border of the tumor and the center of the splenic hilum is \<3cm on preoperative imaging; * Locally advanced PDAC according to the NCCN definition or distant metastasis; * Previous abdominal surgery in which the short gastric and/or left gastroepiploic vessels were ligated (e.g. gastrectomy, gastric sleeve, fundoplication), resulting in the impossibility of performing a Warshaw (spleen-vessel resecting) procedure; * Pregnancy.